Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

Company Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $12.65 to $15.32
• 50-Day Range: $7.34 to $17.78
• 52-Week Range: $2.03 to $14.36
• Volume: 168,864 shs
• Average Volume: 50,104 shs
• Market Capitalization: $140.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NLTX Stock Analysis - Frequently Asked Questions

How have NLTX shares performed this year?

Neoleukin Therapeutics' stock was trading at $22.86 at the beginning of the year. Since then, NLTX stock has decreased by 34.4% and is now trading at $15.00.
View the best growth stocks for 2025 here.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($5.60) EPS for the quarter, meeting the consensus estimate of ($5.60).

When did Neoleukin Therapeutics' stock split?

Shares of Neoleukin Therapeutics reverse split on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), GE Aerospace (GE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NLTX
• CIK: 1404644
• Web: www.neoleukin.com
• Phone: (866) 245-0312
• Fax: 778-331-4486
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,560,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.22%
• Return on Assets: -30.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.33
• Quick Ratio: 15.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.08 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 9,398,000
• Free Float: 9,250,000
• Market Cap: $122.46 million
• Optionable: No Data
• Beta: 1.11